The FDA advanced a proposed rule aimed at simplifying drug establishment registration for factories supporting the U.S. market. The rule is designed to streamline how regulated manufacturing sites are registered and update processes for distributed biopharma manufacturing, with an explicit focus on strengthening the supply chain. The proposal sits alongside the agency’s broader push to reduce administrative friction in drug production oversight, which can affect how quickly sponsors and contract manufacturers can move from planning into registration and production activity. For biotech operators, the practical impact is tied to compliance timelines, documentation burden, and clarity around distributed manufacturing coverage.